TR199701520T1 - Cell lineage that produces analgesic compounds for pain relief. - Google Patents

Cell lineage that produces analgesic compounds for pain relief.

Info

Publication number
TR199701520T1
TR199701520T1 TR97/01520T TR9701520T TR199701520T1 TR 199701520 T1 TR199701520 T1 TR 199701520T1 TR 97/01520 T TR97/01520 T TR 97/01520T TR 9701520 T TR9701520 T TR 9701520T TR 199701520 T1 TR199701520 T1 TR 199701520T1
Authority
TR
Turkey
Prior art keywords
pain relief
cell lineage
analgesic compounds
produces analgesic
produces
Prior art date
Application number
TR97/01520T
Other languages
Turkish (tr)
Inventor
Saydoff Joel
Wong Shou
Original Assignee
Cytotherapeutics,Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cytotherapeutics,Inc. filed Critical Cytotherapeutics,Inc.
Publication of TR199701520T1 publication Critical patent/TR199701520T1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0071—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/665—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/665—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • C07K14/70—Enkephalins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production

Abstract

Acinin iyilestirilmesi için en azindan bir katekolamin, en azindan bir endorfin ve en azindan bir enkefalini üreten genetik mühendisliginden geçirilmis hücre soyu.Hücreler, dogrudan ihtiyaç duyan bir hastaya temin edilebilir,ya da bir biyo-yapay organin olusturulmasi için kapsüllenebilir.Genetically engineered cell line that produces at least one catecholamine, at least one endorphine, and at least one encephaline for the healing of pain.

TR97/01520T 1995-06-07 1996-06-07 Cell lineage that produces analgesic compounds for pain relief. TR199701520T1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US48191795A 1995-06-07 1995-06-07

Publications (1)

Publication Number Publication Date
TR199701520T1 true TR199701520T1 (en) 1998-04-21

Family

ID=23913905

Family Applications (1)

Application Number Title Priority Date Filing Date
TR97/01520T TR199701520T1 (en) 1995-06-07 1996-06-07 Cell lineage that produces analgesic compounds for pain relief.

Country Status (20)

Country Link
EP (1) EP0833935A1 (en)
JP (1) JPH11507530A (en)
KR (1) KR19990022414A (en)
CN (1) CN1192246A (en)
AR (1) AR004494A1 (en)
AU (1) AU6263696A (en)
BR (1) BR9608746A (en)
CA (1) CA2223246A1 (en)
CZ (1) CZ392497A3 (en)
EE (1) EE9700326A (en)
HU (1) HUP9901191A2 (en)
IL (1) IL122415A0 (en)
IN (1) IN181898B (en)
IS (1) IS4628A (en)
NO (1) NO975545L (en)
PL (1) PL323867A1 (en)
SK (1) SK167997A3 (en)
TR (1) TR199701520T1 (en)
WO (1) WO1996040959A1 (en)
ZA (1) ZA964880B (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999028449A2 (en) * 1997-11-28 1999-06-10 Medical Research Council Yac vectors
WO2000016799A1 (en) 1998-09-23 2000-03-30 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Methods of treating chronic pain
EP1127121B1 (en) * 1998-10-27 2005-12-14 Anticancer, Inc. Construction d'une retrovirus exprimant le locus mel de streptomyces, et son expression dans des cellules mammiferes
US6372489B1 (en) 1998-10-27 2002-04-16 Anticancer, Inc. Method and model for hair pigmentation
US6903244B1 (en) 1999-02-26 2005-06-07 University Of Utah Research Foundation Mice which are +/− or −/− for the elastin gene as models for vascular disease
AU2002952993A0 (en) 2002-11-29 2002-12-12 The Corporation Of The Trustees Of The Order Of The Sisters Of Mercy In Queensland Therapeutic and diagnostic agents
JP2007516984A (en) 2003-12-24 2007-06-28 ザ ウォルター アンド エリザ ホール インスティテュート オブ メディカル リサーチ Therapeutic substances and uses therefor
US8741635B2 (en) 2004-05-12 2014-06-03 The Walter And Eliza Hall Institute Of Medical Research Method of cell isolation
WO2006135985A1 (en) 2005-06-24 2006-12-28 The Walter And Eliza Hall Institute Of Medical Research Therapeutic pro-apoptotic bh3-like molecules and methods for generating and/or selecting the same
EP2051726B1 (en) 2006-07-18 2018-04-18 University of Utah Research Foundation Methods for treating pain and screening analgesic compounds
US8889173B2 (en) * 2008-04-18 2014-11-18 Warsaw Orthopedic, Inc. Alpha adrenergic receptor agonists for treatment of pain and/or inflammation
CA2913993A1 (en) 2013-05-31 2014-12-04 University Of Utah Research Foundation Conotoxin peptides, pharmaceutical compositions and uses thereof
JP6877419B2 (en) 2015-10-27 2021-05-26 ザ ユニバーシティー オブ クイーンズランド Treatment methods and agents useful for them
CN107964047B (en) * 2017-12-18 2018-11-02 哈尔滨工业大学 Chimeric peptide and its synthetic method based on Tyr-Pro-Trp-Phe-NH2 and neurotensin (8-13) and application
CN112891337A (en) * 2021-03-26 2021-06-04 河北医科大学 Application of galangin and its derivatives in preparing medicine for preventing and treating nervous system diseases

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7568094A (en) * 1993-08-12 1995-03-14 Cytotherapeutics, Inc. Improved compositions and methods for the delivery of biologically active molecules using genetically altered cells contained in biocompatible immunoisolatory capsules

Also Published As

Publication number Publication date
BR9608746A (en) 1999-05-11
AR004494A1 (en) 1998-12-16
EE9700326A (en) 1998-06-15
IN181898B (en) 1998-10-24
SK167997A3 (en) 1998-05-06
ZA964880B (en) 1997-01-07
PL323867A1 (en) 1998-04-27
AU6263696A (en) 1996-12-30
HUP9901191A2 (en) 1999-08-30
IS4628A (en) 1997-12-04
KR19990022414A (en) 1999-03-25
JPH11507530A (en) 1999-07-06
NO975545L (en) 1998-02-04
IL122415A0 (en) 1998-06-15
CA2223246A1 (en) 1996-12-19
CN1192246A (en) 1998-09-02
WO1996040959A1 (en) 1996-12-19
NO975545D0 (en) 1997-12-02
EP0833935A1 (en) 1998-04-08
CZ392497A3 (en) 1998-12-16

Similar Documents

Publication Publication Date Title
TR199701520T1 (en) Cell lineage that produces analgesic compounds for pain relief.
DE69738667D1 (en) PREVENTATION AND TREATMENT OF COLONADOMENO OR COLONMICROADENOMA WITH 6-FLUORO-SODEOXYCHOLIC ACID
BR0015110A (en) Methods of treating cell proliferative diseases, of treating a disorder associated with ksp kinesin activity, of ksp kinesin inhibition, of kps kinesin modulators and of screening compounds that bind ksp kinesin, and compounds
GEP20033092B (en) Purine Inhibitors of Cyclin Dependent Kinase 2 and Ik-Aa
DE69129861T2 (en) TOPICAL AGENTS FOR THE TRANSDERMAL ADMINISTRATION OF PRODRUG DERIVATIVES OF MORPHINE
EP0946147A4 (en) Treatment of equine laminitis
GB9807639D0 (en) Anti-inflammatory agents
DE69735848D1 (en) DOSE FORM WITH INCREASING DOSE RELIEF
HK1050860A1 (en) Nordihydroguaiaretic derivatives for use in treatment of tumors
DE69522012T2 (en) CANCER TREATMENT
TR199800644T2 (en) y-RAR antagonist ligand or alpha-RAR antagonist ligand as an apoptosis inhibitor.
AU3139097A (en) Methods of preventing skeletal problems in poultry
HK1047707A1 (en) Use of (+)-tramadol, o-demethyltramadol or (+)-o-demethyltramadol, o-desmethyl-n-mono-desmethyl-tramadol or (+)-o-desmethyl-n-mono-desmethyl-tramadol for treating urinary incontinence
ATE526944T1 (en) SELF TANNING COMPOSITIONS THAT CONTAIN CHOLESTEROL SULFATE AND DHA
ATE293986T1 (en) PAIN RELIEVING USE OF N-L-ALPHA-ASPARTYL-L-PHENYLALANINE-1-METHYL ESTER
DE69633396D1 (en) PHARMACEUTICAL COMPOSITION CONTAINING ACTIVIN STIMULATOR
NO984760L (en) Use of an osmolyte in the treatment of effects caused by an infection, inflammation or immune dysfunction
DE69626816D1 (en) USE OF SELEGILIN FOR THE TREATMENT OF HEARING LOSS IN MAMMALS
MD1569G2 (en) Method of treatment of breast canceeeer in the preoperation period
IT1290910B1 (en) 2-OPTICALLY ACTIVE AMINOTETRALINE, PROCEDURE FOR ITS PREPARATION AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN IT, ACTIVE
TR199802496T2 (en) Formulation for the treatment of congestive heart failure.
TR199801492A2 (en) Methods of obtaining sulfonamide-substituted compounds.
MD916G2 (en) Ungent for stomatologic deseases treatment
IL126157A0 (en) Method for treating excessive aggression
MX9709828A (en) Cell line producing analgesic compounds for treating pain.